(Q37398870)

English

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

scientific article published on 23 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study (English)

1 reference

Europe PubMed Central

20 August 2017

0 references

1 reference

based on heuristic

inferred from title

systemic lupus erythematosus

0 references

monoclonal antibody

1 reference

based on heuristic

inferred from title

Munther A. Khamashta

1

object named as

Munther Khamashta

1 reference

Europe PubMed Central

20 August 2017

2

object named as

Joan T Merrill

1 reference

Europe PubMed Central

20 August 2017

Kenneth C. Kalunian

5

object named as

Kenneth Kalunian

1 reference

Europe PubMed Central

20 August 2017

author name string

Victoria P Werth

3

1 reference

Europe PubMed Central

20 August 2017

Richard Furie

4

1 reference

Europe PubMed Central

20 August 2017

Gabor G Illei

6

1 reference

Europe PubMed Central

20 August 2017

Jorn Drappa

7

1 reference

Europe PubMed Central

20 August 2017

Liangwei Wang

8

1 reference

Europe PubMed Central

20 August 2017

Warren Greth

9

1 reference

Europe PubMed Central

20 August 2017

CD1067 study investigators

10

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

23 March 2016

1 reference

Europe PubMed Central

20 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

20 August 2017

75

1 reference

Europe PubMed Central

20 August 2017

11

1 reference

Europe PubMed Central

20 August 2017

1909-1916

1 reference

Europe PubMed Central

20 August 2017

Blockade of interferon-γ normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Type I interferon blockade in systemic lupus erythematosus: where do we stand?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Interferon-α abrogates the suppressive effect of apoptotic cells on dendritic cells in an in vitro model of systemic lupus erythematosus pathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Anti-interferon alpha treatment in SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Biomarkers for systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Glucocorticoid use and abuse in SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Quality of life in cutaneous lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

The interferon-alpha signature of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Building a measure of fatigue: the functional assessment of Chronic Illness Therapy Fatigue Scale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Numerical scoring for the BILAG-2004 index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Novel evidence-based systemic lupus erythematosus responder index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Lupus: improving long-term prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Mortality in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Type I interferon correlates with serological and clinical manifestations of SLE

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Systemic lupus erythematosus and the type I interferon system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Long-term outcomes in lupus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

6 September 2017

Systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

2 September 2018

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5099191

2 September 2018

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208562

21 January 2018

BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha: a new target for therapy in systemic lupus erythematosus?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic lupus erythematosus disease activity index 2000

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2015-208562

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37398870&oldid=1704250450"